JP2017536812A5 - - Google Patents

Download PDF

Info

Publication number
JP2017536812A5
JP2017536812A5 JP2017520920A JP2017520920A JP2017536812A5 JP 2017536812 A5 JP2017536812 A5 JP 2017536812A5 JP 2017520920 A JP2017520920 A JP 2017520920A JP 2017520920 A JP2017520920 A JP 2017520920A JP 2017536812 A5 JP2017536812 A5 JP 2017536812A5
Authority
JP
Japan
Prior art keywords
molecule
cell
composition
provides
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017520920A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017536812A (ja
JP6821561B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/056217 external-priority patent/WO2016061574A1/en
Publication of JP2017536812A publication Critical patent/JP2017536812A/ja
Publication of JP2017536812A5 publication Critical patent/JP2017536812A5/ja
Application granted granted Critical
Publication of JP6821561B2 publication Critical patent/JP6821561B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017520920A 2014-10-17 2015-10-19 バイパータイト型およびトリパータイト型のシグナル伝達免疫細胞 Active JP6821561B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462065138P 2014-10-17 2014-10-17
US62/065,138 2014-10-17
US201562151315P 2015-04-22 2015-04-22
US62/151,315 2015-04-22
PCT/US2015/056217 WO2016061574A1 (en) 2014-10-17 2015-10-19 Bipartite and tripartite signaling immune cells

Publications (3)

Publication Number Publication Date
JP2017536812A JP2017536812A (ja) 2017-12-14
JP2017536812A5 true JP2017536812A5 (enExample) 2018-11-15
JP6821561B2 JP6821561B2 (ja) 2021-01-27

Family

ID=55747478

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017520920A Active JP6821561B2 (ja) 2014-10-17 2015-10-19 バイパータイト型およびトリパータイト型のシグナル伝達免疫細胞

Country Status (5)

Country Link
US (1) US20170246278A1 (enExample)
EP (2) EP3207147A4 (enExample)
JP (1) JP6821561B2 (enExample)
MA (2) MA41538A (enExample)
WO (1) WO2016061574A1 (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9511092B2 (en) 2013-01-28 2016-12-06 St. Jude Children's Research Hospital, Inc. Chimeric receptor with NKG2D specificity for use in cell therapy against cancer and infectious disease
KR20210014210A (ko) 2014-05-15 2021-02-08 내셔널 유니버시티 오브 싱가포르 변형된 천연 살해 세포 및 그의 용도
US20170258835A1 (en) * 2014-10-31 2017-09-14 The Trustees Of The University Of Pennsylvania Methods and compositions for modified t cells
JP7170394B2 (ja) 2015-01-31 2022-11-14 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 治療用分子のt細胞送達のための組成物および方法
US20170151281A1 (en) 2015-02-19 2017-06-01 Batu Biologics, Inc. Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer
GB201514875D0 (en) 2015-08-20 2015-10-07 Autolus Ltd Receptor
MA44334A (fr) 2015-10-29 2018-09-05 Novartis Ag Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
US11325948B2 (en) 2016-03-19 2022-05-10 Exuma Biotech Corp. Methods and compositions for genetically modifying lymphocytes to express polypeptides comprising the intracellular domain of MPL
US11111505B2 (en) 2016-03-19 2021-09-07 Exuma Biotech, Corp. Methods and compositions for transducing lymphocytes and regulating the activity thereof
CA3030003A1 (en) * 2016-07-08 2018-01-11 F1 Oncology, Inc. Methods and compositions for transducing lymphocytes and regulating the activity thereof
KR20230167769A (ko) * 2016-08-26 2023-12-11 베이롤 칼리지 오브 메드신 세포 치료요법을 위한 항상성 활성 사이토킨 수용체
EP3518944A4 (en) * 2016-09-30 2020-06-17 Baylor College of Medicine ADAPTIVE CHIMERIC ANTIGENT RECEPTOR T-CELL DESIGN
GB201702617D0 (en) * 2017-02-17 2017-04-05 Autolus Ltd Receptor
BR112019020001A2 (pt) 2017-03-27 2020-04-28 Nat Univ Singapore linhagens celulares estimuladoras para expansão ex vivo e ativação de células exterminadoras naturais
IL269553B2 (en) 2017-03-27 2025-10-01 Nat Univ Singapore Truncated NKG2D chimeric receptors and their uses in immunotherapy with natural killer cells
WO2019109980A1 (zh) * 2017-12-06 2019-06-13 科济生物医药(上海)有限公司 嵌合蛋白、表达嵌合蛋白的免疫效应细胞及其应用
US20190192678A1 (en) * 2017-12-18 2019-06-27 Novather, Inc. System and method for the treatment of disease using a hyperspecific modified protein system
JP7374434B2 (ja) * 2018-02-09 2023-11-07 国立大学法人大阪大学 改良されたαβT加工細胞製造方法
JP7360174B2 (ja) 2018-02-09 2023-10-12 ナショナル ユニヴァーシティー オブ シンガポール ナチュラルキラー細胞免疫療法における活性化キメラ受容体及びその使用
US10780120B2 (en) 2018-03-06 2020-09-22 The Trustees Of The University Of Pennsylvania Prostate-specific membrane antigen cars and methods of use thereof
JP7334985B2 (ja) 2018-04-02 2023-08-29 ナショナル ユニヴァーシティー オブ シンガポール 免疫細胞で発現される膜結合抗サイトカイン非シグナル伝達バインダーによるヒトサイトカインの中和
AU2019330347B2 (en) 2018-08-29 2025-07-24 National University Of Singapore A method to specifically stimulate survival and expansion of genetically-modified immune cells
US12240915B2 (en) 2018-08-30 2025-03-04 Innovative Cellular Therapeutics Holdings, Ltd. Chimeric antigen receptor cells for treating solid tumor
EP3876977A1 (en) 2018-11-06 2021-09-15 The Regents Of The University Of California Chimeric antigen receptors for phagocytosis
WO2020180882A1 (en) 2019-03-05 2020-09-10 Nkarta, Inc. Cd19-directed chimeric antigen receptors and uses thereof in immunotherapy
TW202110873A (zh) 2019-04-30 2021-03-16 美商聖堤生物科技股份有限公司 嵌合受體及其使用方法
US11026973B2 (en) 2019-04-30 2021-06-08 Myeloid Therapeutics, Inc. Engineered phagocytic receptor compositions and methods of use thereof
BR112022003553A2 (pt) * 2019-08-30 2022-05-24 Allogene Therapeutics Inc Receptores de citocina quiméricos compreendendo domínios de ligação a tgf beta
MX2022002613A (es) 2019-09-03 2022-06-02 Myeloid Therapeutics Inc Metodos y composiciones para la integracion del genoma.
US10980836B1 (en) 2019-12-11 2021-04-20 Myeloid Therapeutics, Inc. Therapeutic cell compositions and methods of manufacturing and use thereof
US12076343B2 (en) 2020-02-19 2024-09-03 Innovative Cellular Therapeutics Holdings, Ltd. Engineered safety in cell therapy
US12043654B2 (en) 2020-06-02 2024-07-23 Innovative Cellular Therapeutics Holdings, Ltd. Anti-GCC antibody and CAR thereof for treating digestive system cancer
WO2022016112A1 (en) 2020-07-17 2022-01-20 Instil Bio (Uk) Limited Receptors providing targeted costimulation for adoptive cell therapy
JP2023549140A (ja) 2020-11-04 2023-11-22 マイエロイド・セラピューティクス,インコーポレーテッド 操作されたキメラ融合タンパク質組成物およびその使用方法
AU2022237618A1 (en) 2021-03-17 2023-10-12 Create Medicines, Inc. Engineered chimeric fusion protein compositions and methods of use thereof
WO2022241029A1 (en) 2021-05-11 2022-11-17 Myeloid Therapeutics, Inc. Methods and compositions for genomic integration
TW202306997A (zh) 2021-06-16 2023-02-16 英商英斯特生物科技有限公司 用於在過繼細胞療法中提供標靶共刺激之受體
WO2023288278A1 (en) 2021-07-16 2023-01-19 Instil Bio (Uk) Limited Chimeric molecules providing targeted costimulation for adoptive cell therapy

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5906936A (en) 1988-05-04 1999-05-25 Yeda Research And Development Co. Ltd. Endowing lymphocytes with antibody specificity
US6319494B1 (en) 1990-12-14 2001-11-20 Cell Genesys, Inc. Chimeric chains for receptor-associated signal transduction pathways
US5843728A (en) 1991-03-07 1998-12-01 The General Hospital Corporation Redirection of cellular immunity by receptor chimeras
GB9304200D0 (en) 1993-03-02 1993-04-21 Sandoz Ltd Improvements in or relating to organic compounds
IL104570A0 (en) 1992-03-18 1993-05-13 Yeda Res & Dev Chimeric genes and cells transformed therewith
US5712149A (en) 1995-02-03 1998-01-27 Cell Genesys, Inc. Chimeric receptor molecules for delivery of co-stimulatory signals
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
US7435596B2 (en) 2004-11-04 2008-10-14 St. Jude Children's Research Hospital, Inc. Modified cell line and method for expansion of NK cell
US8822647B2 (en) 2008-08-26 2014-09-02 City Of Hope Method and compositions using a chimeric antigen receptor for enhanced anti-tumor effector functioning of T cells
KR101629071B1 (ko) * 2008-10-08 2016-06-09 인트렉손 코포레이션 다수의 면역조절자를 발현하는 조작된 세포 및 그 용도
MX347656B (es) * 2011-04-08 2017-05-08 Baylor College Medicine Inversion de los efectos del micro-ambiente de tumor utilizando receptores de citocina quimericos.
AU2013221672B2 (en) * 2012-02-13 2017-11-09 Seattle Children's Hospital D/B/A Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
US20130280220A1 (en) * 2012-04-20 2013-10-24 Nabil Ahmed Chimeric antigen receptor for bispecific activation and targeting of t lymphocytes
WO2014055657A1 (en) * 2012-10-05 2014-04-10 The Trustees Of The University Of Pennsylvania Use of a trans-signaling approach in chimeric antigen receptors
US9597357B2 (en) * 2012-10-10 2017-03-21 Sangamo Biosciences, Inc. T cell modifying compounds and uses thereof
EP2986636B1 (en) * 2013-04-17 2018-11-14 Baylor College Of Medicine Immunosuppressive tgf-beta signal converter

Similar Documents

Publication Publication Date Title
JP2017536812A5 (enExample)
IL314563A (en) Non-HLA-restricted T-cell receptors and their uses
Rezvani et al. Engineering natural killer cells for cancer immunotherapy
IL276593A (en) Improved methods for producing adoptive cell therapies
ES2671004T3 (es) Dirección a CD138 en cáncer
IL309526B2 (en) TGFBeta signal converter
Ruella et al. Adoptive immunotherapy for cancer
Figueroa et al. Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy
Kershaw et al. Gene-engineered T cells for cancer therapy
JP2019535275A5 (enExample)
HRP20210116T1 (hr) Poboljšane kompozicije t stanica
JP2021505131A5 (enExample)
RU2017114174A (ru) Композиции и способы для бустинга эффективности адоптивной клеточной иммунотерапии
JP2019513347A5 (enExample)
JP2016513458A5 (enExample)
RU2017121115A (ru) Генетически модифицированные гамма дельта т-клетки
JP2016510597A5 (enExample)
JP2018510160A5 (enExample)
JP2014512183A5 (enExample)
JP2017531687A5 (enExample)
Leisegang et al. T-Cell Receptor Gene–Modified T Cells with Shared Renal Cell Carcinoma Specificity for Adoptive T-Cell Therapy
JP2016520302A5 (enExample)
JP2017503472A5 (enExample)
JP2015535689A5 (enExample)
CA2909701A1 (en) Immunosuppressive tgf-.beta. signal converter